Puig Brands, S.A. (PUGBY) Q2 2026 Earnings Call Transcript
Puig Brands, S.A. (PUGBY) Shareholder/Analyst Call Transcript
Puig Brands, S.A. (PUGBY) Q1 2026 Sales/Trading Call Transcript
Puig Brands, S.A. (PUGBY) Q4 2025 Earnings Call Transcript
Shares in Puig Brands jumped after the beauty group said it could reach its full-year targets despite concerns over a downturn.
Puig Brands, S.A. (OTCPK:PUGBY) Q3 2025 Earnings Call October 30, 2025 1:15 AM EDT Company Participants Marc Puig Guasch - Chairman & CEO Joan Ramis - Chief Financial Officer Conference Call Participants Patrick Folan - Barclays Bank PLC, Research Division Mariano Szachtman - Banco Santander, S.A.
Puig Brands offers an attractive investment opportunity, trading at a significant discount despite strong 1H25 results and a robust luxury brand portfolio. PUGBY reported 6% revenue growth, high margins, and outperformed the beauty market, with premium brands driving over 70% of annual revenues. Valuation is compelling at a 13.4x P/E, with a price target of €20/share and 23% annualized upside; a "BUY" rating is reiterated.
Puig Brands offers strong fundamentals, iconic luxury brands, and attractive growth in fragrance, skincare, and makeup, yet trades at a significant discount. Recent earnings outperformance and a reconfirmed 2025 forecast highlight robust demand and margin stability across all segments, despite tariff headwinds. The current 10-12x P/E valuation is unjustified for a company of Puig's caliber; I assign a fair value of 15x P/E, targeting €20/share.
Puig Brands, known for luxury brands like Rabanne and Carolina Herrera, saw a significant revenue increase in 2024. The company's 2024 net income was 530M EUR, with an EPS of 0.98 EUR, driven by strong cash flows and strategic acquisitions. For 2025, Puig anticipates a 6-8% revenue increase and a slightly higher EBITDA margin, despite potential impacts from US tariffs.
Puig Brands reported a 10% revenue increase in H1, with gross profit growing faster than revenue despite a 17% rise in marketing expenses. Non-recurring IPO-related expenses significantly impacted H1 results, but these are not expected to recur, suggesting stronger net income in H2. Adjusted EBITDA rose by 7.4% to 410M EUR, with stable net debt at 1.5B EUR, indicating strong financial health and potential for debt reduction.